Related references
Note: Only part of the references are listed.Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma
Susanne Flach et al.
BRITISH JOURNAL OF CANCER (2022)
Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer
Silvia Waldeck et al.
MOLECULAR ONCOLOGY (2022)
Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer
Marwan Fakih et al.
JAMA NETWORK OPEN (2022)
Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP).
Marla Lipsyc-Sharf et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Three-year disease-free survival in randomized trials of chemotherapy and HER2-targeted therapy: A meta-analysis.
Abhenil Mittal et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
Jeanne Tie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel
Bolivar Arboleda et al.
ONCOLOGIST (2022)
Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS)
Leonor Benhaim et al.
EUROPEAN JOURNAL OF CANCER (2021)
Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy
Shengnan Jin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
Martine Piccart et al.
LANCET ONCOLOGY (2021)
Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
Bin Qiu et al.
NATURE COMMUNICATIONS (2021)
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
Everett J. Moding et al.
CANCER DISCOVERY (2021)
CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer
Hiroya Taniguchi et al.
CANCER SCIENCE (2021)
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer
Aparna R. Parikh et al.
CLINICAL CANCER RESEARCH (2021)
Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
Lionel Larribere et al.
CANCERS (2021)
Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
Yan Peng et al.
FRONTIERS IN ONCOLOGY (2021)
Outcomes of renal cell carcinoma with associated venous tumor thrombus: experience from a large cohort and short time span in a single center
Zhigang Chen et al.
BMC CANCER (2021)
How I treat stage II colon cancer patients
J. Taieb et al.
ESMO OPEN (2021)
Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases
De-Shen Wang et al.
THERANOSTICS (2021)
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions
Michael L. Cheng et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer
Tej D. Azad et al.
GASTROENTEROLOGY (2020)
MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer
Shelize Khakoo et al.
CLINICAL CANCER RESEARCH (2020)
Tobacco smoking and somatic mutations in human bronchial epithelium
Kenichi Yoshida et al.
NATURE (2020)
Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer
Jian Yang et al.
CELL DEATH & DISEASE (2020)
The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA
Tenna V. Henriksen et al.
MOLECULAR ONCOLOGY (2020)
Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring
Asaf Zviran et al.
NATURE MEDICINE (2020)
Risk factors and risk prediction models for colorectal cancer metastasis and recurrence: an umbrella review of systematic reviews and meta-analyses of observational studies
Wei Xu et al.
BMC MEDICINE (2020)
Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer
Jiahong Jiang et al.
FRONTIERS IN ONCOLOGY (2020)
Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer
Muyun Peng et al.
FRONTIERS IN ONCOLOGY (2020)
Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer
Everett J. Moding et al.
NATURE CANCER (2020)
Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study
Jeanne Tie et al.
GUT (2019)
Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA
L. Tan et al.
ANNALS OF ONCOLOGY (2019)
Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer
Vincent P. Groot et al.
CLINICAL CANCER RESEARCH (2019)
Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence
Raoul Charles Coombes et al.
CLINICAL CANCER RESEARCH (2019)
Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma
Emil Christensen et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Detection of Solid Tumor Molecular Residual Disease(MRD) Using Circulating Tumor DNA (ctDNA)
Re-I Chin et al.
MOLECULAR DIAGNOSIS & THERAPY (2019)
Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer
Yuxuan Wang et al.
JAMA ONCOLOGY (2019)
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
Thomas Reinert et al.
JAMA ONCOLOGY (2019)
Timing of Adjuvant Chemotherapy and Survival in Colorectal, Gastric, and Pancreatic Cancer. A Systematic Review and Meta-Analysis
Fausto Petrelli et al.
CANCERS (2019)
Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer
B. Lee et al.
ANNALS OF ONCOLOGY (2019)
Perioperative Dynamic Changes in Circulating Tumor DNA in Patients with Lung Cancer (DYNAMIC)
Kezhong Chen et al.
CLINICAL CANCER RESEARCH (2019)
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer
Bradon R. McDonald et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer
N. Tarazona et al.
ANNALS OF ONCOLOGY (2019)
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
Jeanne Tie et al.
JAMA ONCOLOGY (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort
Alexandre Lafourcade et al.
BMC CANCER (2018)
Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study
Peng Gao et al.
BMC CANCER (2018)
False-Positive Plasma Genotyping Due to Clonal Hematopoiesis
Yuebi Hu et al.
CLINICAL CANCER RESEARCH (2018)
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
A. Grothey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study.
Charles Swanton et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Christopher Abbosh et al.
NATURE (2017)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
N. Masuda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Direct detection of early-stage cancers using circulating tumor DNA
Jillian Phallen et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
Aadel A. Chaudhuri et al.
CANCER DISCOVERY (2017)
Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer
Lone V. Scholer et al.
CLINICAL CANCER RESEARCH (2017)
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
Jeanne Tie et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease
Eleonor Olsson et al.
EMBO MOLECULAR MEDICINE (2015)
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Isaac Garcia-Murillas et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients
Mark Sausen et al.
NATURE COMMUNICATIONS (2015)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Minimal residual disease in solid neoplasia: New frontier or red-herring?
Pierre Mordant et al.
CANCER TREATMENT REVIEWS (2012)
Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
Ramaswamy Govindan et al.
CELL (2012)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
K. Albain et al.
LANCET (2012)
Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up
S. Pignata et al.
ANNALS OF ONCOLOGY (2011)
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Gordon J. S. Rustin et al.
LANCET (2010)
Local Recurrence After Surgery for Early Stage Lung Cancer An 11-Year Experience With 975 Patients
Chris R. Kelsey et al.
CANCER (2009)
Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials
Daniel Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group
Jean-Pierre Pignon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Circulating mutant DNA to assess tumor dynamics
Frank Diehl et al.
NATURE MEDICINE (2008)
What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data
MJ Sweeting et al.
STATISTICS IN MEDICINE (2004)
Meta-analysis of observational studies in epidemiology - A proposal for reporting
DF Stroup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Share Paper
